EarlyStage Valuation In TheBiotechnology IndustryVinay RanadeFebruary
Early-Stage Valuation in the
Biotechnology Industry
Vinay Ranade
February 2008
THE WALTER H. SHORENSTEIN ASIA-PACIFIC RESEARCH
CENTER (Shorenstein APARC) is a unique Stanford University institution focused on the interdisciplinary study of contemporary Asia.
Shorenstein APARC’s mission is to produce and publish outstanding interdisciplinary, Asia-Pacific–focused research; educate students, scholars, and corporate and governmental affiliates; promote constructive interaction to influence U.S. policy toward the Asia-Pacific; and guide
Asian nations on key issues of societal transition, development, U.S.Asia relations, and regional cooperation.
The Walter H. Shorenstein
Asia-Pacific Research Center
Freeman Spogli Institute for International Studies
Stanford University
Encina Hall
Stanford, CA 94306-6055 http://shorenstein.stanford.edu
About the Author
Vinay Ranade is chief executive officer of GeneMedix plc, an Alternative Investment
Market (AIM) company listed on the London Stock Exchange. GeneMedix is engaged in the business of research, development, manufacturing, and marketing of biosimilars
(biopharmaceutical products) in Europe. GeneMedix is a subsidiary of Reliance Life
Sciences, a research-led, biotechnology initiative of the Reliance Group of Companies,
India. Ranade is a chartered accountant (CPA), qualified in India, and a management graduate of the Asian Institute of Management, Manila, Philippines. Ranade has worked in investment banking in India, both in capital market and project finance groups. He has also worked with Faber-Castell India and was part of the core team that set up Faber-Castell’s Indian business and operations, with specific responsibility for finance and procurement functions. He joined Reliance Life Sciences in 2001 and handled corporate development, finance, procurement, and materials management functions.
Abstract
Biotechnology (or biotech) has impacted almost every aspect of human life. It has reorganized
Biotechnology Industry
Vinay Ranade
February 2008
THE WALTER H. SHORENSTEIN ASIA-PACIFIC RESEARCH
CENTER (Shorenstein APARC) is a unique Stanford University institution focused on the interdisciplinary study of contemporary Asia.
Shorenstein APARC’s mission is to produce and publish outstanding interdisciplinary, Asia-Pacific–focused research; educate students, scholars, and corporate and governmental affiliates; promote constructive interaction to influence U.S. policy toward the Asia-Pacific; and guide
Asian nations on key issues of societal transition, development, U.S.Asia relations, and regional cooperation.
The Walter H. Shorenstein
Asia-Pacific Research Center
Freeman Spogli Institute for International Studies
Stanford University
Encina Hall
Stanford, CA 94306-6055 http://shorenstein.stanford.edu
About the Author
Vinay Ranade is chief executive officer of GeneMedix plc, an Alternative Investment
Market (AIM) company listed on the London Stock Exchange. GeneMedix is engaged in the business of research, development, manufacturing, and marketing of biosimilars
(biopharmaceutical products) in Europe. GeneMedix is a subsidiary of Reliance Life
Sciences, a research-led, biotechnology initiative of the Reliance Group of Companies,
India. Ranade is a chartered accountant (CPA), qualified in India, and a management graduate of the Asian Institute of Management, Manila, Philippines. Ranade has worked in investment banking in India, both in capital market and project finance groups. He has also worked with Faber-Castell India and was part of the core team that set up Faber-Castell’s Indian business and operations, with specific responsibility for finance and procurement functions. He joined Reliance Life Sciences in 2001 and handled corporate development, finance, procurement, and materials management functions.
Abstract
Biotechnology (or biotech) has impacted almost every aspect of human life. It has reorganized